Australia's most trusted
source of pharma news
Thursday, 21 November 2024
Posted 19 November 2024 AM
There were wild swings in market cap between Q2 and Q3 this year for some of the Top 20 Pharma Companies but industry as a whole is doing better, according to analysts, with a two per cent across the board uplift considered a sign of budding recovery.
Pharma has been doing it tough this year with many companies slimming down their teams and cutting costs in the face of tightening economic pressures.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.